open access

Vol 13, No 6 (2017)
Case report
Published online: 2018-01-04
Get Citation

Effectiveness of nivolumab in an elderly patient with metastatic BRAF-negative melanoma originating from the anal region

Jacek Calik
DOI: 10.5603/OCP.2017.0032
·
Oncol Clin Pract 2017;13(6):308-310.

open access

Vol 13, No 6 (2017)
CASE REPORTS
Published online: 2018-01-04

Abstract

High serum concentration of lactate dehydrogenase (LDH) is associated with poor prognosis in patients with metastatic cutaneous melanoma. Herein, we present a case of a 92-year-old patient with metastatic melanoma and negative prognostic factors treated with anti-PD-1 antibody nivolumab. The therapy yielded excellent clinical results: significant regression of metastatic lesions and improvement in the patient’s performance status. The presented case confirms previously reported observations regarding high clinical activity and acceptable safety profile of nivolumab in elderly patients.

Abstract

High serum concentration of lactate dehydrogenase (LDH) is associated with poor prognosis in patients with metastatic cutaneous melanoma. Herein, we present a case of a 92-year-old patient with metastatic melanoma and negative prognostic factors treated with anti-PD-1 antibody nivolumab. The therapy yielded excellent clinical results: significant regression of metastatic lesions and improvement in the patient’s performance status. The presented case confirms previously reported observations regarding high clinical activity and acceptable safety profile of nivolumab in elderly patients.
Get Citation

Keywords

melanoma, senior age, anti-PD-1, nivolumab

About this article
Title

Effectiveness of nivolumab in an elderly patient with metastatic BRAF-negative melanoma originating from the anal region

Journal

Oncology in Clinical Practice

Issue

Vol 13, No 6 (2017)

Article type

Case report

Pages

308-310

Published online

2018-01-04

DOI

10.5603/OCP.2017.0032

Bibliographic record

Oncol Clin Pract 2017;13(6):308-310.

Keywords

melanoma
senior age
anti-PD-1
nivolumab

Authors

Jacek Calik

References (8)
  1. Brudnik U, Wojas-Pelc A, Branicki W. Genetyczne uwarunkowania czerniaka. Post Dermatol Alergol. 2006; 1: 21–25.
  2. Callahan MK, Wolchok JD. At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy. J Leukoc Biol. 2013; 94(1): 41–53.
  3. Elias R, Morales J, Rehman Y, et al. Immune Checkpoint Inhibitors in Older Adults. Curr Oncol Rep. 2016; 18(8): 47.
  4. Krzakowski M, Warzocha K. Zalecenia postępowania diagnostyczno - terapeutycznego w nowotworach złośliwych. Via Medica, Gdańsk 2013: 422.
  5. Mackiewicz J, Kwinta Ł. Nowe terapie celowane stosowane u chorych na czerniaka uogólnionego. Współczesna Onkologia. 2010; 14(1): 15–22.
  6. Ruka W, Nowecki Z, Rutkowski P. Czerniaki skóry u dorosłych monografia. Medipage. 2005: Warszawa.
  7. Rutkowski P. Nowotwory złośliwe skóry. Via Medica 2014.
  8. Scolyer RA, Long GV, Thompson JF. Evolving concepts in melanoma classification and their relevance to multidisciplinary melanoma patient care. Mol Oncol. 2011; 5(2): 124–136.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl